Litigation drives up Sulzer Medica's loss to $717 million
This article was originally published in Clinica
Swiss company Sulzer Medica suffered a SFr1.19 billion ($717 million) net loss in 2001, mainly as a result of the US litigation over its faulty hip and knee implants, which the company concedes had put its survival in question. However, the Zurich-based company did see total sales rise by 5% to SFr1.42 billion.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.